Weight Loss Drug Market Booms As Employers Weigh Costs And Benefits

GLP-1 drugs like Ozempic and Wegovy have fueled explosive growth for pharmaceutical companies like Novo Nordisk.
These drugs show promise in treating chronic kidney disease, potentially reducing dialysis needs.
U.S. employers covering these medications could nearly double in 2024, raising costs.
While sales of unhealthy foods may be impacted, overall effects on consumer industries remain uncertain.
Despite concerns, the popularity of GLP-1 drugs continues to rise amid obesity epidemic.